Lumiradx receives ce mark for two multiplex tests: lumiradx dual-target sars-cov-2 star complete and lumiradx sars-cov-2 & flu a/b rna star complete

London , june 8, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx) today announced that it has achieved ce mark for two new fast lab solutions molecular tests, including dual-target sars-cov-2 star complete and sars-cov-2 & flu a/b rna star complete. these high-sensitivity and high-throughput tests help to expand testing capabilities across the globe.
LMDX Ratings Summary
LMDX Quant Ranking